Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board
Corporate updatesPharming Group N.V. announces today that the Board of Directors has nominated Dr. Richard Peters to become Pharming’s new Chairman.
Pharming Group to report second quarter and first half 2023 financial results on August 3
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023.
Pharming CEO Sijmen de Vries wins Chief Executive of the Year Award
Other updatesPharming is delighted to announce that CEO Sijmen de Vries was the winner of the Chief Executive of the Year Award at the 2023 European Mediscience Awards in London on Thursday evening. Scroll down for the Dutch translation.
Pharming announces sale of priority review voucher
Financial updatesPharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive agreement with Novartis Pharma A.G. (“Novartis") to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing.
Pharming Group to attend the following Investor Conferences in June
Conference attendancePharming Group N.V. announces that Pharming’s management will attend the following investor conferences in the month of June:
Pharming Group reports on results of the 2023 Annual General Meeting of Shareholders
Financial updatesPharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, the proposal for a specific authorization for the issuance of shares (or rights to acquire shares) to finance mergers, acquisitions, or strategic alliances, was not put up for a vote. All other proposals were approved.
Pharming Group reports financial results for the first quarter of 2023
Financial updatesPharming Group N.V. presents its preliminary, unaudited financial report for the first quarter ended March 31, 2023.
Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023
Conference attendancePharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries will attend the H.C. Wainwright BioConnect Investor Conference 2023 on May 2, 2023 in New York and will take part in a fireside chat at 11:00 ET/17:00 CEST.
Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023
Conference attendancePharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries and Chief Financial Officer, Jeroen Wakkerman will attend the Van Lanschot Kempen Life Sciences Conference on April 25 and 26, 2023 in Amsterdam, the Netherlands.
Notice of First Quarter 2023 Results
Financial updatesPharming Group N.V. confirms it will announce first quarter 2023 financial results for the month ended March 31, 2023 on Thursday, May 11, 2023.